Status:
COMPLETED
Monitoring the IgG/IgM Antibodies in COVID-19 Patients
Lead Sponsor:
University of Sargodha
Collaborating Sponsors:
Shanghai Jiao Tong University School of Biomedical engineering
Conditions:
COVID-19 Infections
Eligibility:
All Genders
18-60 years
Brief Summary
The COVID-19 was declared a global pandemic by WHO more than a year ago, and the world is still experiencing a state of global emergency. This disease is caused by a novel RNA coronavirus suspected to...
Detailed Description
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) pandemic has affected millions of people around the globe. Despite many efforts to find some effective medicines against SARS CoV-2, still ...
Eligibility Criteria
Inclusion
- Suspected/PCR positive COVID-19 patients
- Patients aged \>18 years and \< 60 year
- Able to fill/understand/answer the questionnaire and provide consent to use of personal health information.
Exclusion
- Impaired/disable patients who can not understand or provide questionnaire answers
- Patients aged \<18 years and \> 60 year
Key Trial Info
Start Date :
June 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2022
Estimated Enrollment :
373 Patients enrolled
Trial Details
Trial ID
NCT04810117
Start Date
June 15 2021
End Date
April 30 2022
Last Update
July 21 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Sargodha, Sub campus Bhakkar
Bhakkar, Punjab Province, Pakistan, 30000
2
University of Sargodha
Sargodha, Punjab Province, Pakistan, 40100